(Q35058556)

English

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

10

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jorge Eduardo Cortes

4

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

5

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

6

object named as

Elias Jabbour

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Gautam Borthakur

7

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

object named as

Sherry Pierce

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Guillermo Garcia-Manero

2

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jean-Pierre J Issa

1

object named as

Jean-Pierre Issa

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

object named as

Mark Brandt

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

object named as

Xuelin Huang

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

21 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

121

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

556-561

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320000

8 July 2018

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29085

21 January 2018

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29085

21 January 2018

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29085

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29085

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35058556&oldid=1744043428"